Table 3. Comparison of reasons given for willingness to enroll in RCT, by disclosure arm.
| Standard disclosure (n = 67)a |
Enhanced disclosure (n = 45)a |
|
|---|---|---|
| n (%) | n (%) | |
| Altruism | 13 (19.4) | 16 (35.6) |
| Direct benefit to self (e.g. potential for efficacy when other treatments have failed, improved efficacy, fewer side-effects of investigational drug) | 30 (44.8) | 10 (22.2) |
| Indirect benefits (e.g. close monitoring and access to top clinicians associated with RCT) | 3 (4.5) | 1 (2.2) |
| Financial incentive (explain) | 3 (4.5) | 1 (2.2) |
| Negatives of study are acceptable (e.g. low enough risk, acceptable burdens on time, can return to treatment after the trial) | 6 (9.0) | 8 (17.8) |
| Other | 10 (14.9) | 6 (13.3) |
| No response | 2 (3.0) | 3 (6.7) |
a
The number of coded comments, not participants. The denominator for percentages in this table is the total number of coded comments from those who expressed preference for RCT in each disclosure arm.